Michael Burton Williams, MD
About Michael Burton Williams, MD
Michael Burton Williams, MD, serves as the Executive Director of Biotech Investment Banking at Piper Sandler in New York, NY, where he has worked since 2012. He holds an MD from Brown Medical School, an MBA from the University of Chicago Booth School of Business, and an MPH from Harvard T.H. Chan School of Public Health.
Work at Piper Sandler
Michael Burton Williams serves as the Executive Director of Biotech Investment Banking at Piper Sandler. He has held this position since 2012, contributing to the firm for over a decade. His role involves overseeing investment banking activities focused on the biotechnology sector, leveraging his extensive background in medicine and business to guide clients through complex financial transactions.
Education and Expertise
Michael Burton Williams has a robust educational background. He earned a Master of Public Health (MPH) from Harvard T.H. Chan School of Public Health. He also holds a Master of Business Administration (MBA) from The University of Chicago Booth School of Business. Additionally, he completed his medical degree (MD) at Brown Medical School and studied at the Geisel School of Medicine at Dartmouth, enhancing his expertise in both healthcare and finance.
Background
Michael Burton Williams has a diverse academic and professional background that combines medicine and finance. His training in medicine provides him with a deep understanding of the healthcare industry, while his business education equips him with the skills necessary for investment banking. This unique combination positions him effectively within the biotech sector.
Achievements
Throughout his career, Michael Burton Williams has made significant contributions to the field of biotech investment banking. His tenure at Piper Sandler reflects his commitment to advancing the financial interests of biotechnology firms. His educational qualifications from prestigious institutions further underscore his expertise and capability in navigating the complexities of the biotech industry.